We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

22 hedge funds and large institutions have $1.93M invested in Theriva Biologics in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.08% more ownership

Funds ownership: 0% → 0.08% (+0.08%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

52% less funds holding

Funds holding: 46 → 22 (-24)

74% less capital invested

Capital invested by funds: $7.28M → $1.93M (-$5.35M)

89% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 27

Holders
22
Holders Change
-24
Holders Change %
-52.17%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
4
Closed
27
Calls
$13.6M
Puts
–
Net Calls
+$13.6M
Net Calls Change
+$12.4M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$200K
2
VF
Virtu Financial
New York
+$149K
3
Jane Street
Jane Street
New York
+$82.9K
4
TSS
Two Sigma Securities
New York
+$42K
5
MAM
Meeder Asset Management
Ohio
+$9.95K

Top Sellers

Rank Fund Capital Flow
1
MP
MSD Partners
New York
-$984K
2
William Blair & Company
William Blair & Company
Illinois
-$529K
3
Millennium Management
Millennium Management
New York
-$48K
4
Northern Trust
Northern Trust
Illinois
-$41K
5
Creative Planning
Creative Planning
Kansas
-$40K

TOVX Hedge Fund Activity: Q3 2018 in Review

22 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2018, worth a combined $1.93M — down 74% from $7.28M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of TOVX and 3 opened new positions — a net loss of 24 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $200K. The largest seller was MSD Partners, exiting entirely with an estimated $984K sold.

  • 22 institutional investors held Theriva Biologics (TOVX) as of Q3 2018, down from 46 in Q2 2018.
  • Funds reported $1.93M of Theriva Biologics stock for Q3 2018, down 74% quarter-over-quarter.
  • 3 funds opened new Theriva Biologics positions in Q3 2018 and 27 closed out, a net change of -24 holders.
  • The largest Theriva Biologics buyer in Q3 2018 was Renaissance Technologies, an estimated $200K added.
  • The largest Theriva Biologics seller in Q3 2018 was MSD Partners, an estimated $984K sold.

Based on aggregated 13F filings for Q3 2018.